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Letters to the EditorRegarding the publication “Rivaroxaban
versus warfarin in patients with non-valvular
atrial fibrillation and stage IV-V chronic kidney
disease”
Saeed Shoar, MD,a Nasrin Shoar, MD,b Mohammad Naderan, MD,c and Venkat R. Modukuru, MDd
Houston, TX; Kashan, Iran; Tehran, Iran; and Manhattan, NY
Dear Editor,
The substituting role of direct oral anticoagulants
gastrointestinal bleeding was higher with rivaroxaban
than with warfarin while the rate of intracranial and other(DOACs) in the treatment of nonvalvular atrial fibrillation
(NVAF) is increasingly recognized in different clinical
settings. The recent publication in the American Heart
Journal is truly a part of this continued effort.1
The need for an alternative anticoagulant is especially
sensed in patients with chronic kidney disease (CKD) due
to its high coexistence with NVAF.2 In such a context,
bleeding events are important endpoints to be measured
and compared between different anticoagulation alterna-
tives to vitamin K antagonists such as warfarin, owing to
the substantially higher risk of bleeding. Interestingly, the
study by Weir et al showed a comparable hazard ratio
(HR) for major bleeding between CKD patients of stage
IV-V receiving rivaroxaban or warfarin. On the contrary,
another study showed a lower HR for bleeding events
leading to hospitalization with DOAC than with warfarin,
across all stages of CKD. However, a decreasing HR for
bleeding was observed ranging from 0.93 to 0.83 and to
0.62 along with decreasing eGFR from N 60 to 30–60 and
to b 30 or on dialysis, respectively.3
While a similar bleeding risk between patients on
rivaroxaban and warfarin in the study by Weir et al can be
the result of enrolling patients with an end-stage renal
disease (ESRD), i.e. stage IV-V only, the association of
renal function variability with the risk of bleeding is
noteworthy of being more elaborated on.4 Moreover, a
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rivaroxaban.
Considering the similar bleeding hazards between
rivaroxaban and warfarin in NVAF patients with stage IV-
V CKD, one might quest the rationality of replacing the
conventionally used vitamin K antagonist with DOACs.
We believe the current study findings can only highlight a
different risk profile for major bleeding across two
different anticoagulants in patients with end-stage renal
disease and the reasonability of using rivaroxaban instead
of warfarin for the sake of safety in this subpopulation of
patients remains questionable.References
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